Erasca
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3115 Merryfield Row Ste 300, San Diego, ...Phone Number
(858) 465-6511Website
www.erasca.comRevenue
$26.6 MillionStock Symbol
ERASIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Erasca
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately 5.5 million new patients diagnosed globally per year. We believe that to effectively shut down a pathway that signals as promiscuously as RAS/MAPK, a holistic approach must be taken to target not just individual nodes, but multiple nodes and cooperative mechanisms in parallel. Consequently, we are pursuing three therapeutic strategies that may be used in combination to comprehensively, and perhaps synergistically, shut down the RAS/MAPK pathway.Explore more
Erasca Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Erasca your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Erasca has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Erasca had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Erasca, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Erasca
Check if Erasca has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Erasca launches new products
Check out if Erasca is spiking on competitors!
Earning: See what the market has to say on Erasca recently announced quarterly report
Recommended Actions
Find VP level buyers at Erasca
Find 2 more new buyers
Compare Similar Companies to Erasca
Compare insights from companies similar to Erasca, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Erasca is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Erasca is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Erasca.
Erasca financials insights
Gather financial insights about Erasca, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$64M
2020
Series B
$200M
2021
Share Placement
$300M
Erasca Tech Stack
A closer look at the technologies used by Erasca
Most Recent Scoops
Hiring Plans
Erasca has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Executive Leadership.
Hiring Plans
Open Position
Open Position
Open Position
Person-Based
Erasca News & Media
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International (NASDAQ: PSIX)Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trialImportant Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf
Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corp. (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL)Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY. Management will participate in a fireside chat on Tuesday, September 15, 2026, at 1:05 pm Easte
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Erasca
Sign Up For FreeTo access detailed company insights
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately... Read More
